

Jesus Garcia-Foncillas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6028397/jesus-garcia-foncillas-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

191
papers

7,720
citations

37
h-index

84
g-index

203
ext. papers

8,751
ext. citations

5.4
avg, IF

5.55
L-index

#	Paper	IF	Citations
191	The Essentials of Multiomics.. <i>Oncologist</i> , 2022 , 27, 272-284	5.7	2
190	MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer Patients.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
189	Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients. <i>Cancers</i> , 2021 , 13,	6.6	1
188	Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
187	Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients. <i>Cancers</i> , 2021 , 13,	6.6	1
186	Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes 2021 , 9,		2
185	Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition". <i>British Journal of Cancer</i> , 2021 , 125, 618-619	8.7	1
184	Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments. <i>Cancers</i> , 2021 , 13,	6.6	6
183	Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
182	Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2021 , 111, 146-157	5.6	2
181	The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance. <i>Cancers</i> , 2021 , 13,	6.6	9
180	Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic mutant colon cancer. <i>Theranostics</i> , 2021 , 11, 3595-3606	12.1	6
179	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021 , 27, 2515-2522	12.9	11
178	Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance. <i>Cancers</i> , 2021 , 13,	6.6	1
177	Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. <i>JAMA Network Open</i> , 2021 , 4, e2116536	10.4	4
176	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. <i>Molecular Diagnosis and Therapy</i> , 2021 , 25, 563-576	4.5	1
175	Precision oncology: a clinical and patient perspective. <i>Future Oncology</i> , 2021 , 17, 3995-4009	3.6	3

174	Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. <i>JCO Oncology Practice</i> , 2021 , 17, e1162-e1169	2.3	
173	Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> , 2020 , 6, 1357-1362	3.7	5
172	The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
171	The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
170	Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1696-1707	6.1	11
169	Therapeutic implications of the PP2A/MET signalling axis in doxorubicin-induced cardiotoxicity and antitumour properties. <i>British Journal of Pharmacology</i> , 2020 , 177, 3850-3851	8.6	
168	Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice. <i>JCO Oncology Practice</i> , 2020 , 16, e298-e305	2.3	1
167	MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. <i>Cancers</i> , 2020 , 12,	6.6	10
166	and Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. <i>Cells</i> , 2020 , 9,	7.9	19
165	Functional and Clinical Impact of CircRNAs in Oral Cancer. <i>Cancers</i> , 2020 , 12,	6.6	12
164	Patient Perspective on the Management of Cancer Pain in Spain. <i>Journal of Patient Experience</i> , 2020 , 7, 1417-1424	1.3	0
163	Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. <i>European Journal of Cancer Care</i> , 2020 , 29, e13213	2.4	
162	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020 , 6, 1461-1471	3.7	26
161	Clinical Impact and Regulation of the circCAMSAP1/ miR-328-5p/E2F1 Axis in Colorectal Cancer. <i>Molecular Therapy</i> , 2020 , 28, 1387-1388	11.7	4
160	MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
159	MicroRNAs in Rectal Cancer: Functional Significance and Promising Therapeutic Value. <i>Cancers</i> , 2020 , 12,	6.6	5
158	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. <i>Oncologist</i> , 2020 , 25, e1428-e1432	5.7	2
157	Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study. <i>Neuroendocrinology</i> , 2020 , 110, 50-62	5.6	4

156	The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	8
155	Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. <i>Journal of Pain Research</i> , 2019 , 12, 2349-2358	2.9	2
154	Diabetes-mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction. <i>Molecular Oncology</i> , 2019 , 13, 1887-1897	7.9	5
153	Letter by Cristóbal et al Regarding Article, "Protein Phosphatase 2A Regulates Cardiac Na Channels". <i>Circulation Research</i> , 2019 , 124, e59	15.7	1
152	UNR/ Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	14
151	Post-translational regulation could determine functional differences between SET alpha and beta isoforms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019 , 186, 638	4.5	0
150	Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	16
149	The Role of MicroRNAs in Hepatoblastoma Tumors. <i>Cancers</i> , 2019 , 11,	6.6	18
148	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. <i>Frontiers in Oncology</i> , 2019 , 9, 849	5.3	67
147	Molecular evidence of field cancerization initiated by diabetes in colon cancer patients. <i>Molecular Oncology</i> , 2019 , 13, 857-872	7.9	8
146	Relevance of the PP2A Pathway in the Molecular Mechanisms of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019 , 61, 658-659	5.7	
145	CAR-T cell and Personalized Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1168, 131-145	5.6	2
144	Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 742-748	3.6	13
143	Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. <i>Pathology and Oncology Research</i> , 2019 , 25, 269-278	2.6	3
142	Targeting the RAS-dependent chemoresistance: The Warburg connection. <i>Seminars in Cancer Biology</i> , 2019 , 54, 80-90	12.7	17
141	Potential contribution of SET and c-MYC deregulation to promote extracellular matrix remodelling in hepatocellular carcinoma. <i>British Journal of Pharmacology</i> , 2018 , 175, 573-574	8.6	1
140	Comment on "MicroRNA-199b-5p attenuates TGF- β -induced epithelial-mesenchymal transition in hepatocellular carcinoma" <i>British Journal of Cancer</i> , 2018 , 118, 1028-1029	8.7	2
139	Dissecting the therapeutic implications of the complex SMAD4 regulatory network in metastatic colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1283-1284	3.6	

138	Cancer and suicidal ideation and behaviours: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2018 , 8, e020463	3	6
137	New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	14
136	The clinical impact of using complex molecular profiling strategies in routine oncology practice. <i>Oncotarget</i> , 2018 , 9, 20282-20293	3.3	8
135	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018 , 63, 48-60	14.4	89
134	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1464-1470	8.7	40
133	EphB2 stem-related and EphA2 progression-related miRNA-based networks in progressive stages of CRC evolution: clinical significance and potential miRNA drivers. <i>Molecular Cancer</i> , 2018 , 17, 169	42.1	24
132	Potential Therapeutic Impact of miR-145 Deregulation in Colorectal Cancer. <i>Molecular Therapy</i> , 2018 , 26, 1399-1400	11.7	8
131	Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients. <i>World Journal of Surgery</i> , 2018 , 42, 3771-3778	3.3	1
130	Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 159-170	12.9	45
129	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. <i>Scientific Reports</i> , 2017 , 7, 41371	4.9	2
128	PP2A plays a key role in inflammation and cancer through tristetraprolin activation. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e11	2.4	6
127	Letter to the Editor: Is miR-199b-3p really involved in the migration ability of bone marrow mesenchymal stem cells?. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 1067	6.5	1
126	Caveolin-1 is Markedly Downregulated in Patients with Early-Stage Colorectal Cancer. <i>World Journal of Surgery</i> , 2017 , 41, 2625-2630	3.3	10
125	Comment on "MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells". <i>British Journal of Cancer</i> , 2017 , 116, e7	8.7	
124	UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. <i>PLoS ONE</i> , 2017 , 12, e0182044	3.7	10
123	A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma. <i>Case Reports in Oncology</i> , 2017 , 10, 493-500	1	1
122	PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017 , 1868, 435-438	11.2	8
121	Targeting PP2A to overcome enzalutamide resistance in AR+ breast tumors. <i>Endocrine-Related Cancer</i> , 2017 , 24, L5-L6	5.7	1

120	Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment. <i>Journal of Clinical Medicine</i> , 2017 , 6,	5.1	57
119	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. <i>Oncotarget</i> , 2017 , 8, 18456-18485	3.3	84
118	Colon cancer modulation by a diabetic environment: A single institutional experience. <i>PLoS ONE</i> , 2017 , 12, e0172300	3.7	5
117	Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. <i>Oncotarget</i> , 2017 , 8, 40169-40180	3.3	15
116	Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer. <i>World Journal of Surgery</i> , 2016 , 40, 1017-8	3.3	
115	Potential therapeutic value of miR-425-5p in metastatic colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2016 , 20, 2213-2214	5.6	11
114	Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy. <i>Pathology Research and Practice</i> , 2016 , 212, 1133-1137	3.4	12
113	Obesity and colorectal cancer: molecular features of adipose tissue. <i>Journal of Translational Medicine</i> , 2016 , 14, 21	8.5	89
112	Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1137-41	2.5	19
111	Downregulation of miR-138 as a Contributing Mechanism to Lcn-2 Overexpression in Colorectal Cancer with Liver Metastasis. <i>World Journal of Surgery</i> , 2016 , 40, 1021-2	3.3	10
110	Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. <i>Oncotarget</i> , 2016 , 7, 47954-47965	3.3	48
109	The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. <i>BioMed Research International</i> , 2016 , 2016, 1869304	3	17
108	Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?. <i>BioMed Research International</i> , 2016 , 2016, 4873089	3	21
107	MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	21
106	Comment on Goldsworthy et al. Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes. <i>Diabetes</i> 2016;65:1434-1446. <i>Diabetes</i> , 2016 , 65, e22-3	0.9	2
105	Deregulation of miR-92a in locally advanced rectal cancer. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 612	5	2
104	Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2016 , 20, 1729-36	5.6	18
103	Cross Talk between Wnt/ECatenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications. <i>Molecular and Cellular Biology</i> , 2016 , 36, 1734-9	4.8	12

102	c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2780-2790	6.1	8
101	Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study. <i>BMC Cancer</i> , 2016 , 16, 519	4.8	11
100	The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2015 , 51, 423-30	4.4	36
99	PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer. <i>Tumor Biology</i> , 2015 , 36, 5753-5	2.9	12
98	Analysis of BRCA1 and mtDNA haplotypes and mtDNA polymorphism in familial breast cancer. <i>Mitochondrial DNA</i> , 2015 , 26, 227-31		12
97	Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. <i>Journal of Translational Medicine</i> , 2015 , 13, 282	8.5	51
96	Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2015 , 15, 132	3.5	18
95	Clinical Value of miR-26b Discriminating Ulcerative Colitis-associated Colorectal Cancer in the Subgroup of Patients with Metastatic Disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, E24-5	4.5	6
94	Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 19447-57	6.3	2
93	Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer. <i>Marine Drugs</i> , 2015 , 13, 3276-86	6	21
92	Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 5903-17	3.3	26
91	MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2015 , 30, 899-906	3	37
90	Actualizaci3n de la recomendaci3n para la determinaci3n de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Espa3ola de Anatom3a Patol3gica y de la Sociedad Espa3ola de Oncolog3a M3dica. <i>Revista Espanola De Patologia</i> , 2015 , 48, 14-24	1.2	1
89	Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 347-56	12.9	49
88	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. <i>Oncotarget</i> , 2015 , 6, 4299-314	3.3	76
87	A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. <i>Neuro-Oncology</i> , 2014 , 16, 520-7	1	236
86	Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2014 , 29, 641	3	6
85	Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis. <i>Journal of Surgical Oncology</i> , 2014 , 110, 484-5	2.8	19

84	Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1031-9	2.2	164
83	Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014 , 1842, 1823-9	6.9	27
82	Downregulation of miR-214 is specific of liver metastasis in colorectal cancer and could play a role determining the metastatic niche. <i>International Journal of Colorectal Disease</i> , 2014 , 29, 885	3	16
81	Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 1249-50	4.9	1
80	PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 938-47	6.1	86
79	DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. <i>BMC Cancer</i> , 2014 , 14, 965	4.8	21
78	Re: Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/ β -catenin signaling. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	1
77	Clinical significance of miR-126 in colorectal cancer. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 881	5	2
76	Endometrial adenocarcinoma in one horn of a didelphic uterus with vaginal duplication. <i>BMJ Case Reports</i> , 2014 , 2014,	0.9	4
75	mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients. <i>Oncology Letters</i> , 2013 , 6, 1343-1345	2.6	11
74	Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2. <i>Genome Biology</i> , 2013 , 14, R104	18.3	182
73	A new palliative care consultation team at the oncology department of a university hospital: an assessment of initial efficiency and effectiveness. <i>Supportive Care in Cancer</i> , 2012 , 20, 2199-203	3.9	25
72	Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 587-93	4	29
71	Recomendaci3n para la determinaci3n de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Espa3ola de Anatom3a Patol3gica y de la Sociedad Espa3ola de Oncolog3a M3dica. <i>Revista Espanola De Patologia</i> , 2012 , 45, 130-144	1.2	3
70	Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2012 , 48, 1774-80	7.5	56
69	Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2012 , 14, 726-39	3.6	18
68	The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. <i>Clinical and Translational Oncology</i> , 2012 , 14, 835-41	3.6	4
67	Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. <i>World Journal of Gastroenterology</i> , 2012 , 18, 637-45	5.6	28

66	Phase II study of oxaliplatin and sorafenib in advanced gastric cancer after failure of cisplatin-fluoropyrimidine-based (PF) treatment.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4079-4079	2.2	4
65	Association between a specific miRNA signature and pathological response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14057-e14057	2.2	4
64	Determina KRAS: A consolidated project.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 428-428	2.2	1
63	Activation of angiogenic pathway in the prediction of pathologic response to bevacizumab-based neoadjuvant therapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10595-10595	2.2	
62	A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation. <i>Oncology Letters</i> , 2011 , 2, 807-809	2.6	
61	A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). <i>Investigational New Drugs</i> , 2011 , 29, 1038-44	4.3	11
60	Treatment recommendations for metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 162-78	3.6	21
59	MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. <i>Stem Cells</i> , 2011 , 29, 1661-71	5.8	222
58	Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. <i>Journal of Surgical Oncology</i> , 2011 , 103, 411-5	2.8	48
57	Patterns of response after preoperative treatment in gastric cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 80, 698-704	4	15
56	Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. <i>Clinical Cancer Research</i> , 2011 , 17, 4155-66 ^{12.9}		40
55	Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. <i>PLoS ONE</i> , 2011 , 6, e26740	3.7	157
54	miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 2265-75	6.1	131
53	Development of a DNA Microelectrochemical Biosensor for CEACAM5 Detection. <i>IEEE Sensors Journal</i> , 2010 , 10, 1368-1374	4	14
52	Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. <i>Clinical and Translational Oncology</i> , 2010 , 12, 533-42	3.6	48
51	A new mutation in the hMSH2 gene in a Spanish Lynch syndrome family. <i>Clinical and Translational Oncology</i> , 2010 , 12, 849-51	3.6	
50	A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family. <i>Breast Cancer Research and Treatment</i> , 2010 , 121, 219-20	4.4	5
49	Comparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 291-3	4.4	2

48	A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on b-lymphocyte lineage cells. <i>Pharmaceutical Research</i> , 2010 , 27, 431-41	4.5	3
47	Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 74, 193-202	7	21
46	microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. <i>Clinical Cancer Research</i> , 2009 , 15, 2281-90	12.9	299
45	miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. <i>Carcinogenesis</i> , 2009 , 30, 1903-9	4.6	282
44	Epigenetic regulation of microRNA expression in colorectal cancer. <i>International Journal of Cancer</i> , 2009 , 125, 2737-43	7.5	372
43	A novel BRCA1 mutation in a Spanish patient with ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 71-3	4.4	1
42	TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. <i>Annals of Surgical Oncology</i> , 2009 , 16, 78-87	3.1	59
41	Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. <i>Lung Cancer</i> , 2009 , 64, 124-6	5.9	6
40	Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer. <i>Onkologie</i> , 2009 , 32, 580-4		21
39	Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 194-202	6.1	51
38	Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents. <i>Journal of Pharmacy and Pharmacology</i> , 2008 , 60, 77-82	4.8	3
37	Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. <i>Cell Research</i> , 2008 , 18, 823-33	24.7	159
36	Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 1753-63	5.6	69
35	Characterization of cisplatin cytotoxicity delivered from PLGA-systems. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008 , 68, 503-12	5.7	31
34	Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. <i>Molecular Cancer Research</i> , 2008 , 6, 1830-40	6.6	168
33	Synthesis and biological evaluation of 2,4,6-functionalized derivatives of pyrido[2,3-d]pyrimidines as cytotoxic agents and apoptosis inducers. <i>Archiv Der Pharmazie</i> , 2008 , 341, 28-41	4.3	10
32	Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2008 , 10, 372-4	3.6	1
31	A novel missense mutation in the CYLD gene in a Spanish family with multiple familial trichoepithelioma. <i>Archives of Dermatology</i> , 2007 , 143, 1209-10		17

30	Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2007 , 15, 1659-69	3.4	132
29	Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. <i>Oral Oncology</i> , 2007 , 43, 713-9	4.4	32
28	Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2007 , 39, 2289-302	5.6	24
27	A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. <i>World Journal of Gastroenterology</i> , 2007 , 13, 2135-7	5.6	13
26	Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. <i>Oncology Reports</i> , 2007 , 17, 325-8	3.5	31
25	A gene signature of 8 genes could identify the risk of recurrence and progression in DukesPB colon cancer patients. <i>Oncology Reports</i> , 2007 , 17, 1089-94	3.5	44
24	Ileal carcinoid tumor with liver metastases and cardiac involvement treated with intraarterial liposomal doxorubicin and valve replacement. <i>Clinical and Translational Oncology</i> , 2006 , 8, 369-71	3.6	3
23	Proteomic analysis in cancer research: potential application in clinical use. <i>Clinical and Translational Oncology</i> , 2006 , 8, 250-61	3.6	23
22	Synthesis and biological evaluation of heteroaryldiamides and heteroaryldiamines as cytotoxic agents, apoptosis inducers and caspase-3 activators. <i>Archiv Der Pharmazie</i> , 2006 , 339, 182-92	4.3	6
21	Structural characteristics of novel symmetrical diaryl derivatives with nitrogenated functions. Requirements for cytotoxic activity. <i>Bioorganic and Medicinal Chemistry</i> , 2006 , 14, 1942-8	3.4	10
20	Gene expression profile of ewing sarcoma cell lines differing in their EWS-FLI1 fusion type. <i>Journal of Pediatric Hematology/Oncology</i> , 2005 , 27, 537-42	1.2	14
19	Synthesis and biological evaluation of new symmetrical derivatives as cytotoxic agents and apoptosis inducers. <i>Bioorganic and Medicinal Chemistry</i> , 2005 , 13, 2031-44	3.4	37
18	Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature. <i>Clinical Lung Cancer</i> , 2005 , 7, 138-40	4.9	9
17	Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. <i>Journal of Neuro-Oncology</i> , 2005 , 73, 189-98	4.8	10
16	Symmetrical Derivatives with Nitrogenated Functions as Cytotoxic Agents and Apoptosis Inducers. <i>Letters in Drug Design and Discovery</i> , 2005 , 2, 341-354	0.8	7
15	Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. <i>Pharmaceutical Research</i> , 2004 , 21, 567-73	4.5	12
14	Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. <i>Oncology</i> , 2003 , 64, 28-35	3.6	106
13	Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. <i>Clinical Colorectal Cancer</i> , 2002 , 2, 104-10	3.8	33

12	Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1779-86	2.2	274
11	N-acetylcysteine downregulates vascular endothelial growth factor production by human keratinocytes in vitro. <i>Archives of Dermatological Research</i> , 2000 , 292, 621-8	3.3	20
10	Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. <i>New England Journal of Medicine</i> , 2000 , 343, 1350-4	59.2	1984
9	CD24 expression on human keratinocytes. <i>Experimental Dermatology</i> , 1998 , 7, 175-8	4	22
8	Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma. <i>Cancer</i> , 1998 , 83, 889-895	6.4	31
7	Alpha-MSH regulates interleukin-10 expression by human keratinocytes. <i>Archives of Dermatological Research</i> , 1998 , 290, 425-8	3.3	48
6	Growth and growth hormone secretion in children with cancer treated with chemotherapy. <i>Journal of Pediatrics</i> , 1997 , 131, 105-12	3.6	29
5	Differential modulation of IL-8 and TNF-alpha expression in human keratinocytes by buflomedil chlorhydrate and pentoxifylline. <i>Experimental Dermatology</i> , 1997 , 6, 186-94	4	14
4	Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. <i>British Journal of Haematology</i> , 1997 , 98, 418-25	4.5	36
3	16-year experience at M. D. Anderson Cancer Center with primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large cell lymphoma. <i>Leukemia and Lymphoma</i> , 1995 , 20, 97-102	1.9	11
2	Chemotherapy-induced growth hormone deficiency in children with cancer. <i>Medical and Pediatric Oncology</i> , 1995 , 25, 90-5		23
1	Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993 , 16, 332-7	2.7	5